Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr-Jun;2(2):185-90.

HAL fluorescence cystoscopy and TURB one year of Romanian experience

Affiliations

HAL fluorescence cystoscopy and TURB one year of Romanian experience

B Geavlete et al. J Med Life. 2009 Apr-Jun.

Abstract

Hexaminolevulinate blue light cystoscopy (HAL-BLC) represents an increasingly acknowledged method in bladder cancer diagnostic. We aimed to evaluate the importance of this procedure in cases of non-invasive bladder tumors (NIBT), to compare it with standard white light cystoscopy (WLC), and to establish the efficiency of blue light transurethral bladder resection (BL-TURB). Between December 2007 and December 2008, WLC and BLC were performed in 70 cases. WL-TURB was performed for all lesions visible in WL, and BL-TURB for those only detected in BL. Patients diagnosed with NIBT were followed-up after an average period of 5 months (between 18 and 22 weeks) by WLC and BLC. The control group included the same number of consecutive cases of NIBT, which underwent only WLC and WL-TURB, as well as the same follow-up protocol as the study group. WLC correctly identified 115 tumors, and BLC, 157 tumors. The detection rate was 68.8% for WLC, with a 9.4% rate of false-positive results, and 94% for BLC, with a 14.6% rate of false-positive results. The diagnostic accuracy in CIS lesions was 57.3% for WLC and 95% for BLC, while in pTa tumors; it was 68.8% for WLC and 94% for BLC. 62 cases of the study group diagnosed with NIBT emphasized a recurrence rate of 6.4% after 5 months. The control group described a recurrence rate of 24.2%. HAL fluorescence cystoscopy is a valuable diagnostic method for patients with NIBT, with considerably improved accuracy by comparison to WLC, and a significant impact upon the short-term recurrence rate.

PubMed Disclaimer

Figures

Fig 1
Fig 1
pT1G1 urothelial bladder tumor visible both in WLC (left) and BLC (right)
Fig 2
Fig 2
Distinctive fluorescent aspect of a pTaG1 tumor, not visible in white light
Fig 3
Fig 3
pTaG1 tumor, visible in white light, with no fluorescence in blue light
Fig 4
Fig 4
CIS lesion, visible only in blue light
Fig 5
Fig 5
Suspicious flat lesion in white light, with no fluorescence in blue light and no pathological confirmation
Fig 6
Fig 6
CIS lesion not visible in white light but fluorescent in blue light
Fig 7
Fig 7
Fluorescent margin of a pT1G2 tumor after WL–TURB, confirmed by pathology
Fig 8
Fig 8
CIS lesion diagnosed only by blue light cystoscopy
Fig 9
Fig 9
CIS lesion omitted by white light
Fig 10
Fig 10
Suspicious lesion in white light, with no fluorescence and no pathological confirmation

Similar articles

Cited by

References

    1. Oosterlinck O, van der Meijden A. Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer. European Association of Urology Guidelines. 2007:1–17.
    1. Loidl W, Schmidbauer J, Susani M. Flexible Cystoscopy assisted by Hexaminolevulinate Induced Fluorescence: A New Approach for Bladder Cancer Detection and Surveillance? Eur Urol. 2005;47:323–326. - PubMed
    1. Fradet Y, Grossman HB, Gomella L. A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter Study. J Urol. 2007;178: 68–73. - PubMed
    1. Schmidbauer J, Witjes F, Schmeller N. Improved Detection of Urothelial Carcinoma In Situ with Hexaminolevulinate Fluorescence Cystoscopy. J Urol. 2004;171:135–138. - PubMed
    1. Grossman HB. Improving the management of bladder cancer with fluorescence cystoscopy. J Environ Pathol Toxicol Oncol. 2007;26:143–147. - PubMed

MeSH terms

LinkOut - more resources